Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Reboxetine: a preliminary report on its use through the Special Access Program.

Kennedy SH, Lam RW, Cohen NL, Rosenbluth M, Sokolov ST, McIntyre RS, Chue P, Craigen G; Canadian Network for Mood and Anxiety Treatments.

J Psychiatry Neurosci. 2002 Nov;27(6):418-22.

2.

Effect of reboxetine on depression in Parkinson's disease patients.

Lemke MR.

J Clin Psychiatry. 2002 Apr;63(4):300-4.

PMID:
12000202
3.

Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.

Katona C, Bercoff E, Chiu E, Tack P, Versiani M, Woelk H.

J Affect Disord. 1999 Oct;55(2-3):203-13.

PMID:
10628889
4.

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.

Berzewski H, Van Moffaert M, Gagiano CA.

Eur Neuropsychopharmacol. 1997 Apr;7 Suppl 1:S37-47; discussion S71-3.

PMID:
9169309
5.

An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder.

Carvalhal AS, de Abreu PB, Spode A, Correa J, Kapczinski F.

J Clin Psychiatry. 2003 Apr;64(4):421-4.

PMID:
12716244
6.

Reboxetine for the treatment of patients with Cocaine Dependence Disorder.

Szerman N, Peris L, Mesías B, Colis P, Rosa J, Prieto A; Grupo de Estudio del Uso de Reboxetina en Dependencia a Cocaina.

Hum Psychopharmacol. 2005 Apr;20(3):189-92.

PMID:
15799010
7.

Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.

Burrows GD, Maguire KP, Norman TR.

J Clin Psychiatry. 1998;59 Suppl 14:4-7. Review.

PMID:
9818623
9.

Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.

Seguí J, López-Muñoz F, Alamo C, Camarasa X, García-García P, Pardo A.

J Psychopharmacol. 2010 Aug;24(8):1201-7. doi: 10.1177/0269881109102641. Epub 2009 Mar 12.

PMID:
19282423
10.

The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study.

Dannon PN, Iancu I, Grunhaus L.

Hum Psychopharmacol. 2002 Oct;17(7):329-33.

PMID:
12415550
11.

Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis.

Pjrek E, Konstantinidis A, Assem-Hilger E, Praschak-Rieder N, Willeit M, Kasper S, Winkler D.

J Psychiatr Res. 2009 May;43(8):792-7. doi: 10.1016/j.jpsychires.2008.11.004. Epub 2009 Feb 23.

PMID:
19230909
12.

Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.

Scates AC, Doraiswamy PM.

Ann Pharmacother. 2000 Nov;34(11):1302-12. Review.

PMID:
11098346
13.

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M.

Mol Psychiatry. 2006 Jul;11(7):680-4. Epub 2006 Feb 21.

PMID:
16491133
14.

The antidepressant efficacy of reboxetine in patients with severe depression.

Montgomery S, Ferguson JM, Schwartz GE.

J Clin Psychopharmacol. 2003 Feb;23(1):45-50.

PMID:
12544375
15.

Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.

Massana J, Möller HJ, Burrows GD, Montenegro RM.

Int Clin Psychopharmacol. 1999 Mar;14(2):73-80.

PMID:
10220121
16.

Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive/hyperactive symptoms: an open-label trial.

Golubchik P, Sever J, Weizman A.

Clin Neuropharmacol. 2013 Mar-Apr;36(2):37-41. doi: 10.1097/WNF.0b013e31828003c1.

PMID:
23503544
17.

Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.

Fava M, McGrath PJ, Sheu WP; Reboxetine Study Group.

J Clin Psychopharmacol. 2003 Aug;23(4):365-9.

PMID:
12920412
18.

The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.

Hajós M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH.

CNS Drug Rev. 2004 Spring;10(1):23-44. Review.

19.
20.

[Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder].

Eker SS, Akkaya C, Akgöz S, Sarandöl A, Kirli S.

Turk Psikiyatri Derg. 2005 Fall;16(3):153-63. Turkish.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk